5.06
+0.16(+3.27%)
Currency In USD
| Previous Close | 4.9 |
| Open | 5.03 |
| Day High | 5.24 |
| Day Low | 4.88 |
| 52-Week High | 14.6 |
| 52-Week Low | 3.79 |
| Volume | 1.01M |
| Average Volume | 953,377 |
| Market Cap | 269.82M |
| PE | -3.8 |
| EPS | -1.33 |
| Moving Average 50 Days | 5.19 |
| Moving Average 200 Days | 6.44 |
| Change | 0.16 |
If you invested $1000 in Candel Therapeutics, Inc. (CADL) since IPO date, it would be worth $722.86 as of July 01, 2025 at a share price of $5.06. Whereas If you bought $1000 worth of Candel Therapeutics, Inc. (CADL) shares 3 years ago, it would be worth $1,576.32 as of July 01, 2025 at a share price of $5.06.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
GlobeNewswire Inc.
Jun 24, 2025 1:05 PM GMT
NEEDHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer
Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer
GlobeNewswire Inc.
Jun 23, 2025 12:05 PM GMT
Interim CFO elevated to permanent role after demonstrating exceptional financial leadership, guiding the company through major operational and financial milestonesNEEDHAM, Mass., June 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel o
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
GlobeNewswire Inc.
Jun 06, 2025 12:05 PM GMT
Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial developmentNEEDHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeuti